Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPA

X
Trial Profile

A phase III parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPA

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ropinirole (Primary) ; Ropinirole
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Hisamitsu Pharmaceutical
  • Most Recent Events

    • 12 May 2020 Primary endpoint (the change from baseline in the total score for the UPDRS Part III (on state) at week 16) has been met, according Results published in the Movement Disorders
    • 12 May 2020 Results published in the Movement Disorders
    • 05 Feb 2019 According to a Kyowa Hakko Kirin medis release, company has announced the results in Feb 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top